Continous, low-dose capecitabine for patients with recurrent colorectal cancer

Romiti, Adriana; ONESTI, Concetta Elisa; Roberto, Michela; Barucca, Viola; Tomao, Silverio; D'Antonio, Chiara; Durante, Valeria; Milano, Annalisa; Falcone, Rosa; Di Rocco, Roberta; Righini, Riccardo; Marchetti, Paolo

doi:10.1007/s12032-015-0496-z

Download

Article (Scientific journals)

Continous, low-dose capecitabine for patients with recurrent colorectal cancer

Romiti, Adriana; ONESTI, Concetta Elisa; Roberto, Michela et al.

2015 • In Medical Oncology, 32 (3), p. 54

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/217580

DOI
10.1007/s12032-015-0496-z

PubMed
25638466

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

metronomica colon.pdf

Publisher postprint (244.27 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Oncology

Author, co-author :

Romiti, Adriana; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

ONESTI, Concetta Elisa ; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Roberto, Michela; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Barucca, Viola; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Tomao, Silverio; Università degli Studi di Roma "La Sapienza"

D'Antonio, Chiara; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Durante, Valeria; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Milano, Annalisa; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Falcone, Rosa; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Di Rocco, Roberta; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Righini, Riccardo; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Marchetti, Paolo; Università degli Studi di Roma "La Sapienza" > Clinical and Molecular Medicine

Language :

English

Title :

Continous, low-dose capecitabine for patients with recurrent colorectal cancer

Publication date :

March 2015

Journal title :

Medical Oncology

ISSN :

1357-0560

eISSN :

1559-131X

Publisher :

Humana Press, Totowa, United States - New Jersey

Volume :

Issue :

Pages :

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 02 January 2018

Statistics

Number of views

142 (1 by ULiège)

Number of downloads

586 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2:733–40.
Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878–86.
Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J Clin Invest. 2000;105:R15–24.
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.
Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumour angiogenesis in mice. J Clin Invest. 2000;105:1045–7.
Romiti A, Cox MC, Sarcina I, et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol. 2013;72:13–33.
Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumour activity and correlation with vascular endothelial growth factor levels. Ann Oncol. 2002;13:73–80.
Allegrini G, Di Desidero T, Barletta MT, et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis. 2012;15:275–86.
Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25 + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–8.
Generali D, Bates G, Berruti A, et al. Immunomodulation of FOXP3 + regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res. 2009;15:1046–51.
Folkins C, Man S, Xu P, et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 2007;67:3560–4.
Lee K, Qian DZ, Rey S, et al. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA. 2009;106:2353–8.
Shi H, Jiang J, Ji J, et al. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer. Cancer Lett. 2014;349:28–35.
Steinbild S, Arends J, Medinger M, et al. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase II study. Onkologie. 2007;30:629–35.
Lin PC, Chen WS, Chao TC, et al. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007;60:351–6.
Lara PM, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol. 2008;26:463–7.
Miger J, Holmqvist A, Sun XF, et al. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med Oncol. 2014;31:870.
Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol. 2008;26:4899–905.
Wong NS, Buckman RA, Clemons M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol. 2010;28:723–30.
Khan OA, Blann AD, Payne MJ, et al. Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer. Br J Cancer. 2011;104:1822–7.
Di Rocco R, Romiti A, Simmaco M, et al. TSER and MTHFR gene polymorphisms and toxicity in cancer patients treated with fluoropyrimidine based chemotherapy. Ann Oncol. 2010;21(Suppl 6):viii248.
Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031–9.